Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Theradex
Roswell Park Cancer Institute
Sanofi
Haukeland University Hospital
Ascentage Pharma Group Inc.
University of Pittsburgh
Eastern Cooperative Oncology Group
First Affiliated Hospital Xi'an Jiaotong University
First Affiliated Hospital of Harbin Medical University
Heidelberg University
Alliance for Clinical Trials in Oncology
University of Leipzig
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)